Escherichia Coli

Total Page:16

File Type:pdf, Size:1020Kb

Escherichia Coli CEACAMs serve as toxin-stimulated receptors for enterotoxigenic Escherichia coli Alaullah Sheikha, Brunda Tumalaa, Tim J. Vickersa, David Alvaradob, Matthew A. Ciorbab, Taufiqur Rahman Bhuiyanc, Firdausi Qadric, Bernhard B. Singerd, and James M. Fleckensteina,e,f,1 aDepartment of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110; bDepartment of Medicine, Division of Gastroenterology, Washington University School of Medicine, Saint Louis, MO 63110; cInternational Centre for Diarrhoeal Disease Research, Bangladesh (ICDDRB), Dhaka, Bangladesh; dInstitute of Anatomy, Medical Faculty, University Duisburg-Essen, 45147 Essen, Germany; eMolecular Microbiology and Microbial Pathogenesis Program, Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO 63110; and fMedicine Service, Veterans Affairs Medical Center, St. Louis, MO 63106 Edited by Ralph R. Isberg, Tufts University School of Medicine, Boston, MA, and approved October 7, 2020 (received for review June 17, 2020) The enterotoxigenic Escherichia coli (ETEC) are among the most com- in enterocyte apical membranes, resulting in a net loss of salt and mon causes of diarrheal illness and death due to diarrhea among water into the lumen of the small intestine and ensuing watery young children in low-/middle-income countries (LMICs). ETEC have diarrheal illness (7). also been associated with important sequelae including malnutrition However, more recent studies have suggested that the molec- and stunting, placing children at further risk of death from diarrhea ular pathogenesis of these organisms is considerably more com- and other infections. Our understanding of the molecular pathogen- plex than had been appreciated (8, 9). One aspect of ETEC esis of acute diarrheal disease as well as the sequelae linked to ETEC virulence which has not been completely explored is the role are still evolving. It has long been known that ETEC heat-labile toxin played by ETEC toxins in mediating pathogen–host interactions. (LT) activates production of cAMP in the cell, signaling the modulation Interestingly, heat-labile toxin has been shown to promote colo- of cellular ion channels that results in a net efflux of salt and water nization of the small intestine in animal models of ETEC infection into the intestinal lumen, culminating in watery diarrhea. However, (10, 11) and to enhance bacterial adhesion in vitro (12). While the as LT also promotes ETEC adhesion to intestinal epithelial cells, we intracellular signaling pathways involved in LT-stimulated adhe- postulated that increases in cAMP, a critical cellular “second messen- sion have been explored (13), the precise mechanism by which LT ” ger, may be linked to changes in cellular architecture that favor promotes pathogen–host interactions remains undefined. MICROBIOLOGY pathogen–host interactions. Indeed, here we show that ETEC use LT Interestingly, E. coli pathovars other than ETEC (14, 15) in- to up-regulate carcinoembryonic antigenrelated cell adhesion mole- teract with certain carcinoembryonic antigen-related cell adhesion cules (CEACAMs) on the surface of small intestinal epithelia, where molecules (CEACAMs), surface glycoproteins belonging to a su- they serve as critical bacterial receptors. Moreover, we show that perfamily of immunoglobulin-like cell adhesion molecules enco- bacteria are specifically recruited to areas of CEACAM expression, in ded on chromosome 19 (16). Each CEACAM possess an amino particular CEACAM6, and that deletion of this CEACAM abrogates terminal Ig-like variable domain and varying numbers of domains both bacterial adhesion and toxin delivery. Collectively, these results homologous to Ig constant region (SI Appendix,Fig.S1A). Data to provide a paradigm for the molecular pathogenesis of ETEC in which date suggest that chromosomally encoded type 1 fimbriae (pili), the bacteria use toxin to drive up-regulation of cellular targets that common to virtually all E. coli, engage these glycoprotein mole- enhances subsequent pathogen–host interactions. cules, including CEA (CD66e, CEACAM5), as well as NCA enterotoxin | CEACAM | diarrhea Significance Escherichia coli he burden of illness caused by enterotoxigenic Enterotoxigenic Escherichia coli (ETEC), a leading cause of acute T(ETEC) is remarkable, with yearly estimates of hundreds of watery diarrheal illness in children, have also been linked to millions of infections worldwide (1). Although the death rate from nondiarrheal sequelae including malnutrition. ETEC produce acute diarrheal illness has declined appreciably in the past few heat-labile toxin (LT) to stimulate the production of cellular decades (2), ETEC and other enteric pathogens have recently cAMP, ultimately modulating ion channels to release salt and been recognized as a cause of substantial morbidity in children water into the intestinal lumen, resulting in diarrhea. Given the who survive the acute infection. Increasingly, these organisms have importance of cAMP as a “second messenger,” we reasoned that been implicated in postdiarrheal sequelae including growth cellular features could be altered by LT to benefit the bacteria. stunting, malnutrition, and cognitive deficiencies, thereby exacting Interestingly, we found that LT-mediated increases in cAMP a tremendous global health burden (3). stimulate production of CEACAMs, a family of cell surface gly- ETEC were discovered as a cause of severe cholera-like di- – coproteins, which then serve as receptors for ETEC. Collectively, arrhea more than five decades ago (4 6), and the ETEC path- our findings may have implications for our understanding of ovar came to be defined as organisms capable of producing heat-labile toxin-mediated illness as well as sequelae associated with these (LT) and/or heat-stable (ST) enterotoxins. LT is a heterohexameric important pathogens. protein, similar to cholera toxin (CT), that is composed of a pentameric B subunit that engages host cell receptors to pro- Author contributions: A.S., M.A.C., B.B.S., and J.M.F. designed research; A.S., B.T., T.J.V., mote uptake of the enzymatically active A subunit. Heat-stable T.R.B., F.Q., and J.M.F. performed research; D.A., M.A.C., T.R.B., F.Q., and B.B.S. contrib- toxins are small peptides of 18 or 19 amino acids that bind to uted new reagents/analytic tools; A.S., B.T., T.J.V., D.A., B.B.S., and J.M.F. analyzed data; guanylate cyclase C. In the canonical paradigm for ETEC patho- and A.S., M.A.C., B.B.S., and J.M.F. wrote the paper. genesis, these organisms adhere to the small intestinal mucosa via The authors declare no competing interest. plasmid-encoded colonization factors, where they deliver their toxin This article is a PNAS Direct Submission. payloads to cognate receptors on intestinal epithelia (7). Toxin- Published under the PNAS license. mediated activation of adenylate cyclase by LT and guanylate cy- 1To whom correspondence may be addressed. Email: [email protected]. clase by ST result in respective production of host cAMP and This article contains supporting information online at https://www.pnas.org/lookup/suppl/ cGMP. Intracellular accumulation of these cyclic nucleotides results doi:10.1073/pnas.2012480117/-/DCSupplemental. in activation of protein kinases that in turn modulate ion channels First published November 2, 2020. www.pnas.org/cgi/doi/10.1073/pnas.2012480117 PNAS | November 17, 2020 | vol. 117 | no. 46 | 29055–29062 Downloaded by guest on September 24, 2021 − − (CD66c, CEACAM6) (17–19), through specific lectin-mediated CEACAM6 / cells in trans by lentiviral transduction with CEA- interactions with mannosylated residues (20, 21). We have re- CAM6, restoring the adhesion phenotype (Fig. 2 E and F). Sim- cently demonstrated that, in addition to plasmid-encoded patho- ilarly, heterologous expression of CEACAM6 in HeLa cells var specific pili, known as colonization factors, the majority of promoted ETEC adhesion (Fig. 2 G–I), and, among the individual ETEC express chromosomally encoded type 1 fimbriae, and that CEACAMs, CEACAM6 expression was most efficient in pro- these structures play an essential role in virulence (22). We moting bacterial adhesion (SI Appendix,Fig.S3A and B). therefore questioned whether CEACAMs expressed in the intes- Earlier studies demonstrated that E. coli can interact not only tine contribute to the pathogenesis of ETEC. Here we demon- with CEACAM6, but also with CEA (CEACAM5) (17–19). While strate that heat-labile toxin stimulates production of CEACAMs we found that treatment of Caco-2 cells with CEACAM5 siRNA that then serve as critical receptors for ETEC type 1 fimbriae, resulted in significant decreases in adhesion, this was not true of − − accelerating bacterial adhesion and toxin delivery to host tissues. CEACAM6 / cells treated with the same siRNA (SI Appendix, Fig. S4A). Moreover, we found that this siRNA treatment resulted Results in decreased production of both CEACAM5 and CEACAM6 (SI Heat-Labile Toxin Induces CEACAM Expression in Intestinal Epithelial Appendix,Fig.S4B). In contrast to distinct localization of bacteria Cells. Of the different CEACAMs, CEACAM1, CEACAM5, and within areas of CEACAM6 expression, we found that ETEC were CEACAM6 are normally expressed predominantly in the colon, not preferentially distributed to areas of CEACAM5 production but also by small intestinal epithelia, while CEACAM7 is largely (SI Appendix,Fig.S4C). Nevertheless, we observed clear areas of restricted to the colon (SI Appendix, Table S1 and Fig. S1B).
Recommended publications
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • CEACAM7 (NM 001291485) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC237032 CEACAM7 (NM_001291485) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: CEACAM7 (NM_001291485) Human Tagged ORF Clone Tag: Myc-DDK Symbol: CEACAM7 Synonyms: CGM2 Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RC237032 representing NM_001291485 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGGGTCCCCTTCAGCCTGTCCATACAGAGTGTGCATTCCCTGGCAGGGGCTCCTGCTCACAGCCTCGC TTTTAACCTTCTGGAACCTGCCAAACAGTGCCCAGACCAATATTGATGTCGTGCCGTTCAATGTCGCAGA AGGGAAGGAGGTCCTTCTAGTAGTCCATAATGAGTCCCAGAATCTTTATGGCTACAACTGGTACAAAGGG GAAAGGGTGCATGCCAACTATCGAATTATAGGATATGTAAAAAATATAAGTCAAGAAAATGCCCCAGGGC CCGCACACAACGGTCGAGAGACAATATACCCCAATGGAACCCTGCTGATCCAGAACGTCACCCACAATGA CGCAGGAATCTATACCCTACACGTTATAAAAGAAAATCTTGTGAATGAAGAAGTAACCAGACAATTCTAC GTATTCTCGGAGCCACCCAAGCCCTCCATCACCAGCAACAACTTCAATCCGGTGGAGAACAAAGATATTG TGGTTTTAACCTGTCAACCTGAGACTCAGAACACAACCTACCTGTGGTGGGTAAACAATCAGAGCCTCCT GGTCAGTCCCAGGCTGCTGCTCTCCACTGACAACAGGACCCTCGTTCTACTCAGCGCCACAAAGAATGAC ATAGGACCCTATGAATGTGAAATACAGAACCCAGTGGGTGCCAGCCGCAGTGACCCAGTCACCCTGAATG TCCGCTATGAGTCAGTACAAGCAAGTTCACCTGACCTCTCAGCTGGGACCGCTGTCAGCATCATGATTGG AGTACTGGCTGGGATGGCTCTGATA ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATT
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • The Regulation of Interleukin 7 Receptor Alpha Internalization, Recycling and Degradation by IL-7
    Universidade de Lisboa Faculdade de Medicina Unidade de Biologia do Cancro, Instituto de Medicina Molecular The regulation of Interleukin 7 receptor alpha internalization, recycling and degradation by IL-7 - Possible implications in T-cell homeostasis, migration and leukaemogenesis - Catarina Martins de Oliveira Henriques Doutoramento em Ciências Biomédicas For the degree of Doctor of Philosophy 2009 Universidade de Lisboa Faculdade de Medicina Unidade de Biologia do Cancro, Instituto de Medicina Molecular The regulation of Interleukin 7 receptor alpha internalization, recycling and degradation by IL-7 - Possible implications in T-cell homeostasis, migration and leukaemogenesis - Catarina Martins de Oliveira Henriques (Recipient of a scholarship- SFRH7BD/21940/2005 from Fundação para a Ciência e Tecnologia) Tese orientada pelo Doutor João T. Barata, Prof Doutor.Gerard Graham e Prof. Doutora Leonor Parreira Doutoramento em Ciências Biomédicas, especialidade em Ciências Biopatológicas For the degree of Doctor of Philosophy 2009 As opiniões expressas são da exclusiva responsabilidade do seu autor A impressão desta dissertação foi aprovada pela Comissão Coordenadora do Conselho Científico da Faculdade de Medicina de Lisboa em reunião de 13 de Outubro de 2009. Para a Prof. Filomena Mota. Sem o seu apoio e inspiração há muitos anos atrás, eu não seria hoje uma bióloga nem esta tese teria alguma vez existido… Table of Contents Table of contents……………………………………………………….………………….................. i Aknowledgements…………………………………………………………………………………………….
    [Show full text]
  • Molecular Characteristics of Circulating Tumor Cells Resemble the Liver Metastasis More Closely Than the Primary Tumor in Metastatic Colorectal Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 37 Research Paper Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer Wendy Onstenk1, Anieta M. Sieuwerts1, Bianca Mostert1, Zarina Lalmahomed2, Joan B. Bolt-de Vries1, Anne van Galen1, Marcel Smid1, Jaco Kraan1, Mai Van1, Vanja de Weerd1, Raquel Ramírez-Moreno1, Katharina Biermann3, Cornelis Verhoef2, Dirk J. Grünhagen2, Jan N.M. IJzermans2, Jan W. Gratama1, John W.M. Martens1, John A. Foekens1, Stefan Sleijfer1 1Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, The Netherlands 2Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands 3Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands Correspondence to: Wendy Onstenk, email: [email protected] Keywords: circulating tumor cells, CTCs, CellSearch, colorectal cancer, gene expression profiling Received: April 06, 2016 Accepted: May 29, 2016 Published: June 20, 2016 ABSTRACT Background: CTCs are a promising alternative for metastatic tissue biopsies for use in precision medicine approaches. We investigated to what extent the molecular characteristics of circulating tumor cells (CTCs) resemble the liver metastasis and/ or the primary tumor from patients with metastatic colorectal cancer (mCRC). Results: The CTC profiles were concordant with the liver metastasis in 17/23 patients (74%) and with the primary tumor in 13 patients (57%). The CTCs better resembled the liver metastasis in 13 patients (57%), and the primary tumor in five patients (22%). The strength of the correlations was not associated with clinical parameters. Nine genes (CDH1, CDH17, CDX1, CEACAM5, FABP1, FCGBP, IGFBP3, IGFBP4, and MAPT) displayed significant differential expressions, all of which were downregulated, in CTCs compared to the tissues in the 23 patients.
    [Show full text]
  • Systemic Surfaceome Profiling Identifies Target Antigens for Immune-Based Therapy in Subtypes of Advanced Prostate Cancer
    Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer John K. Leea,b,c, Nathanael J. Bangayand, Timothy Chaie, Bryan A. Smithf, Tiffany E. Parivaf, Sangwon Yung, Ajay Vashishth, Qingfu Zhangi,j, Jung Wook Parkf, Eva Coreyk, Jiaoti Huangi, Thomas G. Graeberc,d,l,m, James Wohlschlegelh, and Owen N. Wittec,d,f,n,o,1 aDivision of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, CA 90095; bInstitute of Urologic Oncology, Department of Urology, University of California, Los Angeles, CA 90095; cJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095; dDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; eStanford University School of Medicine, Palo Alto, CA 94305; fDepartment of Microbiology, Immunology, and Medical Genetics, University of California, Los Angeles, CA 90095; gYale School of Medicine, New Haven, CT 06510; hDepartment of Biological Chemistry, University of California, Los Angeles, CA 90095; iDepartment of Pathology, Duke University School of Medicine, Durham, NC 27708; jDepartment of Pathology, China Medical University, 110001 Shenyang, People’s Republic of China; kDepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195; lCrump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095; mUCLA Metabolomics Center, University of California, Los Angeles, CA 900095; nParker Institute for Cancer Immunotherapy,
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Literature Mining Sustains and Enhances Knowledge Discovery from Omic Studies
    LITERATURE MINING SUSTAINS AND ENHANCES KNOWLEDGE DISCOVERY FROM OMIC STUDIES by Rick Matthew Jordan B.S. Biology, University of Pittsburgh, 1996 M.S. Molecular Biology/Biotechnology, East Carolina University, 2001 M.S. Biomedical Informatics, University of Pittsburgh, 2005 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2016 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Rick Matthew Jordan It was defended on December 2, 2015 and approved by Shyam Visweswaran, M.D., Ph.D., Associate Professor Rebecca Jacobson, M.D., M.S., Professor Songjian Lu, Ph.D., Assistant Professor Dissertation Advisor: Vanathi Gopalakrishnan, Ph.D., Associate Professor ii Copyright © by Rick Matthew Jordan 2016 iii LITERATURE MINING SUSTAINS AND ENHANCES KNOWLEDGE DISCOVERY FROM OMIC STUDIES Rick Matthew Jordan, M.S. University of Pittsburgh, 2016 Genomic, proteomic and other experimentally generated data from studies of biological systems aiming to discover disease biomarkers are currently analyzed without sufficient supporting evidence from the literature due to complexities associated with automated processing. Extracting prior knowledge about markers associated with biological sample types and disease states from the literature is tedious, and little research has been performed to understand how to use this knowledge to inform the generation of classification models from ‘omic’ data. Using pathway analysis methods to better understand the underlying biology of complex diseases such as breast and lung cancers is state-of-the-art. However, the problem of how to combine literature- mining evidence with pathway analysis evidence is an open problem in biomedical informatics research.
    [Show full text]
  • The Immunomodulatory CEA Cell Adhesion Molecule 6 (CEACAM6/Cd66c) Is a Candidate Receptor for the Influenza a Virus
    bioRxiv preprint doi: https://doi.org/10.1101/104026; this version posted January 30, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The immunomodulatory CEA cell adhesion molecule 6 (CEACAM6/CD66c) is a 2 candidate receptor for the influenza A virus 3 Shah Kamranur Rahmana *, Mairaj Ahmed Ansarib, Pratibha Gaurc, Imtiyaz Ahmada, 4 Chandrani Chakravartya,d, Dileep Kumar Vermaa, Sanjay Chhibbere, Naila Nehalf, 5 Shanmugaapriya Sellathanbyd, Dagmar Wirthc, Gulam Warisb and Sunil K. Lala,g # 6 7 Virology Group, International Centre for Genetic Engineering & Biotechnology, New Delhi, 8 Indiaa. 9 Department of Microbiology and Immunology, H. M. Bligh Cancer Research Laboratories, 10 Rosalind Franklin University of Medicine and Science, Chicago Medical School, North 11 Chicago, Illinois, USAb. 12 Helmholtz Centre for Infection Research, Braunschweig, Germanyc. 13 Department of Biomedical Science, Bharathidasan University, Trichy, Indiad. 14 Microbiology Department, Panjab University, Chandigarh, Indiae. 15 Career Institute of Medical & Dental Sciences and Hospital, Lucknow, Indiaf. 16 School of Science, Monash University, Selangor DE, Malaysiag. 17 18 Running Head: Protein receptor for Influenza A Virus 19 20 # Corresponding author: Professor of Microbiology, School of Science, Monash University, 21 47500 Bandar Sunway, Selangor DE, Malaysia. 22 Email: [email protected]; Telephone: (+603) 551 59606 23 24 * Current address: Department of Pathogen Molecular Biology, London School of Hygiene & 25 Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. 26 1 bioRxiv preprint doi: https://doi.org/10.1101/104026; this version posted January 30, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Systemic Surfaceome Profiling Identifies Target Antigens for Immune-Based Therapy in Subtypes of Advanced Prostate Cancer
    Systemic surfaceome profiling identifies target PNAS PLUS antigens for immune-based therapy in subtypes of advanced prostate cancer John K. Leea,b,c, Nathanael J. Bangayand, Timothy Chaie, Bryan A. Smithf, Tiffany E. Parivaf, Sangwon Yung, Ajay Vashishth, Qingfu Zhangi,j, Jung Wook Parkf, Eva Coreyk, Jiaoti Huangi, Thomas G. Graeberc,d,l,m, James Wohlschlegelh, and Owen N. Wittec,d,f,n,o,1 aDivision of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, CA 90095; bInstitute of Urologic Oncology, Department of Urology, University of California, Los Angeles, CA 90095; cJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095; dDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; eStanford University School of Medicine, Palo Alto, CA 94305; fDepartment of Microbiology, Immunology, and Medical Genetics, University of California, Los Angeles, CA 90095; gYale School of Medicine, New Haven, CT 06510; hDepartment of Biological Chemistry, University of California, Los Angeles, CA 90095; iDepartment of Pathology, Duke University School of Medicine, Durham, NC 27708; jDepartment of Pathology, China Medical University, 110001 Shenyang, People’s Republic of China; kDepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195; lCrump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095; mUCLA Metabolomics Center, University of California, Los Angeles, CA 900095; nParker Institute for Cancer
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]